Latest News for: aaic

Edit

Diranersen Results at AAIC Provide First Evidence That Targeting Tau May Slow Cognitive Decline, Signaling ...

The Pilot News 15 Jul 2026
New data show greater tau reduction at higher doses but strongest clinical signal at lowest dose, raising key questions about optimal dosing in further trials, says the ADDF ... .
Edit

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in ...

Norfolk Daily News 14 Jul 2026
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC ... .
Edit

Biogen at AAIC 2026 Presentation (Biogen Inc)

Public Technologies 14 Jul 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Norfolk Daily News 14 Jul 2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single ... .
Edit

Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 Carriers

Montana Standard 14 Jul 2026
Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics ... .
Edit

ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease

PR Newswire 14 Jul 2026
The publication coincides with a late-breaking presentation at the Alzheimer's Association International Conference (AAIC) 2026, highlighting that beyond demonstrating safety, which was the primary ...
Edit

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) (Cervomed Inc)

Public Technologies 14 Jul 2026
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB).
×